- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02285322
Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study
Current guidelines for the clinical management of hypertension in adults recommend to achieve and maintain blood pressure levels of <140/90 mmHg. However, it is uncertain what proportion of individuals identified with high blood pressure in primary care actually reach blood pressure control, what factors are associated with attainment of control and to what extent blood pressure control attainment is associated with cardiovascular diseases in a contemporary population of individuals diagnosed with high blood pressure.
The aim of this study is to investigate the extent to which patients achieve blood pressure control and associated risk factors, time to attainment of blood pressure control and whether this time is associated with an increased risk of CVD onset, all-cause and cardiovascular disease and end-stage renal disease.
Study Overview
Status
Detailed Description
An increment of 20 mmHg of systolic blood pressure (or approximately equivalent 10 mmHg diastolic blood pressure) is associated with more than a two-fold increase in risk of fatal stroke, and with a two-fold increase in fatal ischemic heart diseases in individuals aged 40-69 years. The management and control of high blood pressure is therefore one of the most important components of primary and secondary strategies for prevention of cardiovascular mortality and morbidity. Current guidelines for the clinical management of hypertension in adults recommend to achieve and maintain blood pressure levels of <140/90 mmHg. However, it is uncertain what proportion of individuals identified with high blood pressure in primary care actually reach blood pressure control, what factors are associated with attainment of control and to what extent blood pressure control attainment is associated with cardiovascular diseases in a contemporary population of individuals diagnosed with high blood pressure. This is important for clinicians and policy decision makers in order to design and implement effective strategies for patient management.
The aim of this study is to investigate the extent to which patients achieve blood pressure control and associated risk factors, time to attainment of blood pressure control and whether this time is associated with an increased risk of CVD onset, all-cause and cardiovascular disease and end-stage renal disease.
The study will use data from the CALIBER data set of clinically collected electronic health record data from England.
This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the National Institute for Health Research (NIHR) and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (Clinical Practice Research Datalink - CPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER data set).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- University College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 18 and over
- Registered with a participating general practice during the study period
- Minimum one year of records prior to study entry meeting CPRD data quality
- Diagnosed with high blood pressure in the period January 1997 - March 2010
Exclusion Criteria:
- Patients without record of gender
- Patients with prior atherosclerotic disease, as recorded in primary care or hospitalisation data
- Patients with less than 6 months of follow-up since diagnosis of high blood pressure
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
BP control reached
Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to <140/90mmHg if aged less than 60 years old, and <150/90mmHg for those of ≥60 years
|
|
BP control not reached
Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
First presentation of cardiovascular disease
Time Frame: 10 years
|
First recorded diagnosis of cardiovascular disease during follow-up: myocardial infarction, stroke (haemorrhagic or ischemic), heart failure, coronary revascularisation
|
10 years
|
|
All-cause mortality
Time Frame: 10 years
|
Recorded death of any cause during follow-up
|
10 years
|
|
Cardiovascular mortality
Time Frame: 10 years
|
Recorded death due to cardiovascular disease during follow-up
|
10 years
|
|
Risk factors for blood pressure control
Time Frame: 10 years
|
Investigation of baseline factors associated with blood pressure control attainment during follow-up
|
10 years
|
|
Coronary revascularisation
Time Frame: 10 years
|
First recorded percutaneous coronary intervention or coronary artery bypass graft (excluding interventions performed within 30 days before or after a diagnosis of myocardial infarction)
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
First presentation of cardiovascular disease
Time Frame: 10 years
|
First recorded diagnosis of cardiovascular disease during follow-up: stable angina pectoris and atrial fibrillation
|
10 years
|
|
End-stage renal disease
Time Frame: 10 years
|
Recorded kidney disease resulting in dialysis or kidney transplantation during follow-up
|
10 years
|
|
Management of high blood pressure
Time Frame: 6 months after cohort entry
|
Description of patient management in the 6 months after diagnosis of high blood pressure in terms of: blood pressure lowering medication start, timing and class; smoking cessation; dietary advice; physical activity; weight and total cholesterol decrease; and HDL-cholesterol increase
|
6 months after cohort entry
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10_164R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Beijing Northland Biotech. Co., Ltd.Not yet recruitingAcute Myocardial Infarction (AMI) | Acute Myocardial Infarction of Anterior Wall | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction With ST Segment Elevation | Acute Myocardial Infarction of Left VentricleChina
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SAWithdrawn
-
Samsung Medical CenterThe Korean Society of CardiologyNot yet recruiting
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationCompletedST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionUnited States, Spain, Netherlands, Canada, Australia, Serbia, Egypt, Switzerland, Hungary, United Kingdom, France, Czechia, Nepal, North Macedonia
-
Harbin Medical UniversityNot yet recruitingNon-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)Acute Myocardial Infarction (AMI) | ST-Segment Elevation Myocardial Infarction(STEMI) | Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)China
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark